Literature DB >> 23794679

Rasmussen encephalitis treated with natalizumab.

Stefan Bittner1, Ole J Simon, Kerstin Göbel, Christian G Bien, Sven G Meuth, Heinz Wiendl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23794679     DOI： 10.1212/WNL.0b013e31829c5ceb

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  25 in total

1.  Blocking immune intrusion into the brain suppresses epilepsy in Rasmussen's encephalitis model.

Authors:  Lawrence Steinman
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

2.  Humanized mouse model of Rasmussen's encephalitis supports the immune-mediated hypothesis.

Authors:  Hania Kebir; Lionel Carmant; François Fontaine; Kathie Béland; Ciprian M Bosoi; Nathalie T Sanon; Jorge I Alvarez; Sébastien Desgent; Camille L Pittet; David Hébert; Marie-Josée Langlois; Rose-Marie Rébillard; Dang K Nguyen; Cécile Cieuta-Walti; Gregory L Holmes; Howard P Goodkin; John R Mytinger; Mary B Connolly; Alexandre Prat; Elie Haddad
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

Review 3.  Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES).

Authors:  Carlos A Pardo; Rima Nabbout; Aristea S Galanopoulou
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 4.  Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances.

Authors:  Sophia Varadkar; Christian G Bien; Carol A Kruse; Frances E Jensen; Jan Bauer; Carlos A Pardo; Angela Vincent; Gary W Mathern; J Helen Cross
Journal:  Lancet Neurol       Date:  2014-02       Impact factor: 44.182

Review 5.  Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis.

Authors:  Marianna Spatola; Josep Dalmau
Journal:  Curr Opin Neurol       Date:  2017-06       Impact factor: 5.710

Review 6.  Does brain inflammation mediate pathological outcomes in epilepsy?

Authors:  Karen S Wilcox; Annamaria Vezzani
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

7.  Sustained Effect of Botulinum Neurotoxin in Myoclonus Owing to Epilepsia Partialis Continua.

Authors:  Janis Rebecca Bedarf; Milena Marek; Christian G Bien; Christian E Elger; Sebastian Paus
Journal:  Mov Disord Clin Pract       Date:  2015-07-15

8.  Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study.

Authors:  Jacqueline A French; Andrew J Cole; Edward Faught; William H Theodore; Annamaria Vezzani; Kore Liow; Jonathan J Halford; Robert Armstrong; Jerzy P Szaflarski; Sarah Hubbard; Jagdish Patel; Kun Chen; Wei Feng; Marco Rizzo; Jacob Elkins; Gabrielle Knafler; Kimberly A Parkerson
Journal:  Neurology       Date:  2021-09-14       Impact factor: 9.910

Review 9.  Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases.

Authors:  Heinz Wiendl; Catharina C Gross; Jan Bauer; Doron Merkler; Alexandre Prat; Roland Liblau
Journal:  Nat Rev Neurol       Date:  2021-05-28       Impact factor: 42.937

10.  Seizure control after late introduction of anakinra in a patient with adult onset Rasmussen's encephalitis.

Authors:  Monika Mochol; Erik Taubøll; Line Sveberg; Bjørn Tennøe; Ketil Berg Olsen; Kjell Heuser; Sigrid Svalheim
Journal:  Epilepsy Behav Rep       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.